Press Release Archive
Press Releases
September 2018
09.14.2018 Research Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress 09.12.2018 Partnerships System1 Announces a $25 Million Series A Funding to Advance Integrated Technology Platform for Neurotherapeutics Discovery 09.12.2018 Vaccines Terry Bradshaw and Pfizer Encourage Boomers to Understand Their Risk for Pneumococcal Pneumonia and Take Action to Help Prevent It 09.11.2018 Research BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study 09.06.2018 Partnerships CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy 09.05.2018 Partnerships 4D Molecular Therapeutics Raises $90 Million Series B Financing 09.05.2018 Medicines Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata 09.04.2018 Finance Pfizer Prices $5,000,000,000 Debt Offering
August 2018
08.30.2018 Research Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy 08.27.2018 Medicines Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle 08.27.2018 Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018 08.22.2018 Research Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.